Cargando…
Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection
In vaccinees who were infected with SARS-CoV in 2003, we observed greater antibody responses against spike and nucleoprotein of both SARS-CoV-2 and SARS-CoV after a single dosage of inactivated SARS-CoV-2 vaccine. After receiving the second vaccination, antibodies against RBD of SARS-CoV-2 Wuhan, Be...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176697/ https://www.ncbi.nlm.nih.gov/pubmed/35615992 http://dx.doi.org/10.1080/22221751.2022.2076613 |
_version_ | 1784722722893332480 |
---|---|
author | Liang, Huang Zheng, Peiyan Wang, Qian Deng, Yijun Liang, Dan Yi, Haisu Cheng, Yuanyi Zhao, Xinwei Ma, Jing Yang, Yidong Hu, Peiyu Zheng, Pingqian Zhang, Yudi Huang, Shuangshuang Lin, Xiancheng Ke, Changwen Niu, Xuefeng Sun, Baoqing Chen, Ling |
author_facet | Liang, Huang Zheng, Peiyan Wang, Qian Deng, Yijun Liang, Dan Yi, Haisu Cheng, Yuanyi Zhao, Xinwei Ma, Jing Yang, Yidong Hu, Peiyu Zheng, Pingqian Zhang, Yudi Huang, Shuangshuang Lin, Xiancheng Ke, Changwen Niu, Xuefeng Sun, Baoqing Chen, Ling |
author_sort | Liang, Huang |
collection | PubMed |
description | In vaccinees who were infected with SARS-CoV in 2003, we observed greater antibody responses against spike and nucleoprotein of both SARS-CoV-2 and SARS-CoV after a single dosage of inactivated SARS-CoV-2 vaccine. After receiving the second vaccination, antibodies against RBD of SARS-CoV-2 Wuhan, Beta, Delta, and recently emerged Omicron are significantly higher in SARS-CoV experienced vaccinees than in SARS-CoV naïve vaccinees. Neutralizing activities measured by authentic viruses and pseudoviruses of SARS-CoV, SARS-CoV-2 Wuhan, Beta, and Delta are greater in SARS-CoV experienced vaccinees. In contrast, only weak neutralizing activities against SARS-CoV-2 and variants were detected in SARS-CoV naïve vaccinees. By 6 months after the second vaccination, neutralizing activities were maintained at a relatively higher level in SARS-CoV experienced vaccinees but were undetectable in SARS-CoV naïve vaccinees. These findings suggested a great possibility of developing a universal vaccine by heterologous vaccination using spike antigens from different SARS-related coronaviruses. |
format | Online Article Text |
id | pubmed-9176697 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-91766972022-06-09 Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection Liang, Huang Zheng, Peiyan Wang, Qian Deng, Yijun Liang, Dan Yi, Haisu Cheng, Yuanyi Zhao, Xinwei Ma, Jing Yang, Yidong Hu, Peiyu Zheng, Pingqian Zhang, Yudi Huang, Shuangshuang Lin, Xiancheng Ke, Changwen Niu, Xuefeng Sun, Baoqing Chen, Ling Emerg Microbes Infect Coronaviruses In vaccinees who were infected with SARS-CoV in 2003, we observed greater antibody responses against spike and nucleoprotein of both SARS-CoV-2 and SARS-CoV after a single dosage of inactivated SARS-CoV-2 vaccine. After receiving the second vaccination, antibodies against RBD of SARS-CoV-2 Wuhan, Beta, Delta, and recently emerged Omicron are significantly higher in SARS-CoV experienced vaccinees than in SARS-CoV naïve vaccinees. Neutralizing activities measured by authentic viruses and pseudoviruses of SARS-CoV, SARS-CoV-2 Wuhan, Beta, and Delta are greater in SARS-CoV experienced vaccinees. In contrast, only weak neutralizing activities against SARS-CoV-2 and variants were detected in SARS-CoV naïve vaccinees. By 6 months after the second vaccination, neutralizing activities were maintained at a relatively higher level in SARS-CoV experienced vaccinees but were undetectable in SARS-CoV naïve vaccinees. These findings suggested a great possibility of developing a universal vaccine by heterologous vaccination using spike antigens from different SARS-related coronaviruses. Taylor & Francis 2022-06-02 /pmc/articles/PMC9176697/ /pubmed/35615992 http://dx.doi.org/10.1080/22221751.2022.2076613 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Coronaviruses Liang, Huang Zheng, Peiyan Wang, Qian Deng, Yijun Liang, Dan Yi, Haisu Cheng, Yuanyi Zhao, Xinwei Ma, Jing Yang, Yidong Hu, Peiyu Zheng, Pingqian Zhang, Yudi Huang, Shuangshuang Lin, Xiancheng Ke, Changwen Niu, Xuefeng Sun, Baoqing Chen, Ling Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection |
title | Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection |
title_full | Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection |
title_fullStr | Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection |
title_full_unstemmed | Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection |
title_short | Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection |
title_sort | broad and durable antibody response after vaccination with inactivated sars-cov-2 in individuals with a history of 2003 sars-cov infection |
topic | Coronaviruses |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176697/ https://www.ncbi.nlm.nih.gov/pubmed/35615992 http://dx.doi.org/10.1080/22221751.2022.2076613 |
work_keys_str_mv | AT lianghuang broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection AT zhengpeiyan broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection AT wangqian broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection AT dengyijun broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection AT liangdan broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection AT yihaisu broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection AT chengyuanyi broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection AT zhaoxinwei broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection AT majing broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection AT yangyidong broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection AT hupeiyu broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection AT zhengpingqian broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection AT zhangyudi broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection AT huangshuangshuang broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection AT linxiancheng broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection AT kechangwen broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection AT niuxuefeng broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection AT sunbaoqing broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection AT chenling broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection |